Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Approves Sculptra(R)Aesthetic, A Facial Injectable For Correction Of Nasolabial Folds And Other Facial Wrinkles
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) approved Sculptra(R)Aesthetic (injectable poly-L-lactic acid) for the correction of shallow to deep nasolabial fold (smile lines) contour deficiencies and other facial wrinkles which are treated with the appropriate injection technique in healthy patients. Sculptra(R)Aesthetic works gradually to offer natural-looking results that can last up to two years.
generic viagra online
Lawmakers Seek Compromise On Health Overhaul Proposals
Democrats and Republicans are saying that they will need to compromise on a government-run public plan if they are to meet the deadline of having a bill on the Senate floor by the August recess, The Associated Press reports.
News of the day
Parents Concerned, But Confused About How To Fix Childhood Obesity
Food, fitness or familyò€¦which one is most to blame for childhood obesity? New research from Mintel shows today"s parents aren"t sure, and they"re feeling overwhelmed and worried as they try to prevent obesity in their own children.
Cardiovascular

Antibody Linked To Chemotherapy Drug Inhibits Ovarian Cancer In Lab

A novel anticancer agent, consisting of a monoclonal antibody linked to a chemotherapy drug, showed substantial antitumor activity in ovarian cancer cell lines and in mice, according to a study published online July 29 in the Journal of the National Cancer Institute. The agent, known as an immunoconjugate, targets a protein, EphA2, which is overexpressed in many human cancers but is absent or expressed at low levels in normal tissues. Anil K. Sood, M.D., of The University of Texas M.D. Anderson Cancer Center in Houston, and colleagues tested the immunoconjugate in ovarian cancer cell lines, where it bound to cells with high levels of EphA2 but not to those without the protein. In mice, the EphA2 immunoconjugate inhibited tumor growth by 85% compared with that in mice treated with a control immunoconjugate, a highly statistically significant difference. In cell lines, its antitumor effects were also statistically significantly related to decreased proliferation and increased apoptosis of tumor cells. Chemotherapy drugs typically affect both tumor and normal tissues, which can result in side effects. The immunoconjugate tested by the in this study allows for highly selective delivery of chemotherapy. "In summary," the authors write, "the findings herein provide a novel EphA2-targeted immunoconjugate with potent antitumor activity in ovarian carcinoma. Further preclinical and clinical developmentò€¦appears to be warranted." Steve Graff Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009